Global Pricing & Access Lead, Rare Neurology

About the role

Alexion, AstraZeneca Rare Disease, is looking for a Director to join its Global Value Access and Pricing (GVAP) team in Barcelona. The role covers Neurology indications, including near-term new product launches and label expansions, with particular focus on the NMOSD indication. It is a strategic position leading portfolio-level market access, pricing and reimbursement strategy across key EU markets, with 3 days working from the office and 2 days from home.

Key responsibilities

• Lead the development of a differentiated value proposition for NMOSD, incorporating evidence generation plans and real-world evidence, and support the GMMA Commercial team on NMOSD lifecycle management milestones.
• Develop global market access and pricing strategies and support their implementation with country access representatives.
• Assess pricing and reimbursement risks and opportunities for Neurology and implement mitigations.
• Create value, access and pricing communication tools such as pricing frameworks, negotiation strategies and toolkits, and update the global reimbursement dossier and market access readiness plans.
• Own the monthly Neurology payer working group and represent the GVAP perspective to the Global Value Sub-Team and Global Launch Team.
• Support the development of Neurology pricing strategy, conduct payer and value assessments, and lead market-level P&R strategies for the top EU Neurology markets.
• Review P&R cases from markets and communicate with GMMA senior leadership on Neurology launches and NMOSD lifecycle management.

Required profile

• More than 6 years of drug development and/or commercialization experience in the pharmaceutical industry.
• Highly specialized rare disease and/or Neurology market access experience.
• Relevant graduate degree (e.g. PhD, PharmD, biomedical sciences, business or economics).
• Experience developing evidence-based value solutions with EU payers or US commercial customers.
• Leadership, initiative and the ability to turn science into a compelling payer value story.
• Knowledge of national and regional payers, insurers and commercial customers; knowledge of cost-effectiveness markets such as the UK, Canada and the Nordics is preferred.